Patient Preference and Adherence
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache
(4197) Total Article Views
Authors: Moore JC, Miner JR
Video presented by Johanna C Moore
Published Date January 2012
Volume 2012:6 Pages 27 - 37
|Received:||08 October 2011|
|Accepted:||02 November 2011|
|Published:||04 January 2012|
Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN, USA
Abstract: Subcutaneous sumatriptan is an effective treatment for pain from acute migraine headache, and can be used in patients with known migraine syndrome and in patients with primary headaches when secondary causes have been excluded. In limited comparative trials, subcutaneous sumatriptan performed in a manner comparable with oral eletriptan and intravenous metoclopramide, was superior to intravenous aspirin and intramuscular trimethobenzamide-diphenhydramine, and was inferior to intravenous prochlorperazine for pain relief. The most common side effects seen with subcutaneous sumatriptan are injection site reactions and triptan sensations. As with all triptans, there is a risk of rare cardiovascular events with subcutaneous sumatriptan and its use should be limited to those without known cerebrovascular disease and limited in those with known cardiovascular risk factors and unknown disease status. In studies of patient preference and tolerability, the subcutaneous formulation has a faster time of onset and high rate of efficacy when compared with the oral formulation, but the oral formulation appears to be better tolerated. It is important to consider the needs of the patient, their past medical history, and what aspects of migraine treatment are most important to the patient when considering treatment of acute migraine or primary headache. Subcutaneous sumatriptan is a good first-line agent for the treatment of pain from acute migraine headaches and primary headaches.
Keywords: sumatriptan, subcutaneous, migraine headache, primary headache
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
"I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.
- Health literacy and health seeking behavior among older men in a middle-income nation
- Prolonged rupture of membranes in term infants: should all babies be screened?
- Increasing access to quality health care for the poor: Community perceptions on quality care in Uganda
- Narcissistic rage: The Achilles’ heel of the patient with chronic physical illness